ACM
AGTC

ACT Capital Management’s Applied Genetic Technologies Corporation AGTC Stock Holding History

ACT Capital Management’s Portfolio AGTC Stock Details AGTC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-20,000
Closed -$60K – 117
2021
Q3 		$60K Hold
20,000
– – 0.03% 101
2021
Q2 		$79K Buy
+20,000
New +$82.9K 0.04% 99

Other funds holding AGTC

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
IVM
InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
AGA
Altrinsic Global Advisors Stamford, Connecticut $2.79B AUM 7.25% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

ACT Capital Management's AGTC Position: Q4 2021 in Review

ACT Capital Management sold out of Applied Genetic Technologies Corporation (AGTC) in Q4 2021, closing a stake of 20,000 shares — an estimated $60K sold.

ACT Capital Management first reported a position in AGTC in Q2 2021 and held it in 2 quarters. The position peaked at $79K in Q2 2021. 55 funds tracked by Wall St. Rank hold AGTC as of Q4 2021.

  • ACT Capital Management reported no remaining Applied Genetic Technologies Corporation position as of Q4 2021 after selling out during the quarter.
  • ACT Capital Management sold 20,000 Applied Genetic Technologies Corporation shares in Q4 2021, an estimated $60K.
  • ACT Capital Management first reported a position in Applied Genetic Technologies Corporation in Q2 2021 and held it in 2 quarters.
  • ACT Capital Management's Applied Genetic Technologies Corporation position peaked at $79K in Q2 2021.
  • 55 funds tracked by Wall St. Rank held Applied Genetic Technologies Corporation as of Q4 2021.

Based on ACT Capital Management's 13F filing for Q4 2021, filed 3 Feb 2022.